IRIS UniCatt

De Sanctis, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.462
NA - Nord America 3.233
AS - Asia 2.756
SA - Sud America 506
AF - Africa 81
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 10.049
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.098
SG - Singapore 1.327
DE - Germania 815
NL - Olanda 732
IT - Italia 689
CN - Cina 539
BR - Brasile 417
SE - Svezia 340
VN - Vietnam 256
FR - Francia 214
IE - Irlanda 139
GB - Regno Unito 130
IN - India 102
JP - Giappone 86
HK - Hong Kong 84
FI - Finlandia 73
CA - Canada 70
ID - Indonesia 68
RU - Federazione Russa 68
BD - Bangladesh 53
TR - Turchia 45
PL - Polonia 44
MX - Messico 38
ES - Italia 37
KR - Corea 37
AR - Argentina 35
UA - Ucraina 31
IQ - Iraq 26
ZA - Sudafrica 24
AT - Austria 23
PK - Pakistan 21
CZ - Repubblica Ceca 17
CH - Svizzera 14
CO - Colombia 14
EC - Ecuador 14
IR - Iran 14
BE - Belgio 13
EG - Egitto 13
MK - Macedonia 13
AE - Emirati Arabi Uniti 12
SA - Arabia Saudita 12
CI - Costa d'Avorio 11
IL - Israele 11
LT - Lituania 11
RS - Serbia 11
PH - Filippine 10
JO - Giordania 8
PA - Panama 8
UZ - Uzbekistan 8
VE - Venezuela 8
RO - Romania 7
MA - Marocco 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
SK - Slovacchia (Repubblica Slovacca) 5
AU - Australia 4
BG - Bulgaria 4
CR - Costa Rica 4
DK - Danimarca 4
DO - Repubblica Dominicana 4
GR - Grecia 4
MY - Malesia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TH - Thailandia 4
UY - Uruguay 4
BY - Bielorussia 3
CL - Cile 3
DZ - Algeria 3
HR - Croazia 3
KE - Kenya 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
AO - Angola 2
BT - Bhutan 2
DM - Dominica 2
LA - Repubblica Popolare Democratica del Laos 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
ME - Montenegro 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GL - Groenlandia 1
Totale 10.027
Salva come PNG Salva come JPEG
Città #
Singapore 782
Amsterdam 692
Ashburn 446
San Jose 344
Chandler 332
Frankfurt am Main 155
New York 151
Rome 132
Beijing 113
Dublin 111
Los Angeles 106
Hefei 105
Milan 98
Tokyo 81
Ho Chi Minh City 77
Hong Kong 76
Dallas 74
Hanoi 69
Jakarta 64
Lauterbourg 64
Tukwila 64
Munich 56
São Paulo 45
Boston 40
Helsinki 38
San Mateo 38
Seoul 35
The Dalles 35
Santa Clara 34
Marseille 33
Moscow 32
Houston 30
Warsaw 29
Boardman 28
Princeton 28
Kent 27
Chicago 26
Council Bluffs 26
Palermo 26
Atlanta 25
Nuremberg 25
Orem 25
Buffalo 24
Denver 24
Poplar 23
Toronto 23
Stockholm 22
Da Nang 20
Dearborn 20
Montreal 20
Ann Arbor 19
Düsseldorf 19
Paris 19
Chennai 18
London 18
Wilmington 18
Bremen 17
Brooklyn 17
Mexico City 17
San Francisco 16
Turku 16
Johannesburg 15
Nanjing 15
Cattolica 14
Nürnberg 14
Pune 14
Augusta 13
Brno 13
Falkenstein 13
Vienna 13
Ankara 12
Brussels 12
Rio de Janeiro 12
Seattle 12
Shanghai 12
Abidjan 11
Belo Horizonte 11
Kish 11
Phoenix 11
Haiphong 10
Jacksonville 10
Lancaster 10
Lappeenranta 10
Manchester 10
Redwood City 10
Salamanca 10
Secaucus 10
Skopje 10
Baghdad 9
Bari 9
Bologna 9
Guangzhou 9
Mumbai 9
Washington 9
Amman 8
City of London 8
Menlo Park 8
Turin 8
Wroclaw 8
Andover 7
Totale 5.606
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 959
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 503
Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA Patients: Development of a New Module 335
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 311
Assessing floppy infants: a new module 212
Oral and Swallowing Abilities Tool (OrSAT) in nusinersen treated patients 202
Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening 191
Developmental milestones in type I spinal muscular atrophy 189
Type I SMA “new natural history”: long-term data in nusinersen-treated patients 165
Onasemnogene abeparvovec in spinal muscular atrophy: predictors of efficacy and safety in naïve patients with spinal muscular atrophy and following switch from other therapies 164
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 160
Gain and loss of upper limb abilities in Duchenne muscular dystrophy patients: A 24-month study 156
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 156
Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data 154
Expanded access program with Nusinersen in SMA type I in Italy: Strengths and pitfalls of a successful experience 153
Predominant distal muscle involvement in spinal muscular atrophy 148
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 148
Can the CHOP-INTEND be used as An Outcome Measure in the First Months of Age? Implications for Clinical Trials and Real World Data 147
Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy 147
Revised upper limb module for spinal muscular atrophy: Development of a new module 146
Type I Spinal Muscular Atrophy patients treated with nusinersen: 4 year follow-up of motor, respiratory and bulbar function 143
De novo partial 13q22-q34 trisomy with typical neurological and immunological findings: A case report with new genetic insights 142
Longitudinal assessments in discordant twins with SMA 141
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 139
Type I spinal muscular atrophy and disease modifying treatments: a nationwide study in children born since 2016 135
Respiratory Needs in Patients with Type 1 Spinal Muscular Atrophy Treated with Nusinersen 134
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 134
Needleless inhaled anesthesia with sevoflurane: Advantages of a simplified approach for children with spinal muscular atrophy undergoing intrathecal administration of nusinersen 133
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 133
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study 133
Revised north star ambulatory assessment for young boys with Duchenne muscular dystrophy 133
Early treatment of type II SMA slows rate of progression of scoliosis 132
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 131
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 128
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 127
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls 124
Nusinersen in type 0 spinal muscular atrophy: should we treat? 124
Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy 123
Sleep disorders in spinal muscular atrophy 117
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 117
Developmental milestones in type I spinal muscular atrophy 117
Revised upper limb module for spinal muscular atrophy: Development of a new module 114
Clinical Variability in Spinal Muscular Atrophy Type III. 114
An observational study of functional abilities in infants, children, and adults with type 1 SMA 111
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 110
Longitudinal Analysis of PUL 2.0 Domains in Ambulant and Non-Ambulant Duchenne Muscular Dystrophy Patients: How do they Change in Relation to Functional Ability? 106
Risdiplam in Type 1 Spinal Muscular Atrophy 105
Development of an academic disease registry for spinal muscular atrophy 105
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 103
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 102
Longitudinal natural history of type I spinal muscular atrophy: A critical review 98
An observational study of functional abilities in infants, children, and adults with type 1 SMA 97
Changes in abilities over the initial 12 months of nusinersen treatment for type II SMA 97
Reply to: The need for evidence-based treatment decisions in spinal muscular atrophy type 0 97
Long term follow-up of scoliosis progression in type II SMA patients 93
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 93
Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded 92
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 91
Prognostic factors for tube feeding in type I SMA patients treated with disease-modifying therapies: a cohort study 87
Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module 87
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 83
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 79
Erratum: Long term natural history data in ambulant boys with duchenne muscular dystrophy: 36-month changes (PLoS ONE (2015) 10:12 (e0144079)) 77
Revised upper limb module for spinal muscular atrophy: 12 month changes 77
Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy 75
An observational study of functional abilities in infants, children, and adults with type 1 SMA 73
Point-of-care lung and diaphragm ultrasound in a patient with spinal muscular atrophy with respiratory distress type 1 71
Hammersmith Functional Motor Scale and Motor Function Measure-20 in non ambulant SMA patients 67
Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3 65
Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool 57
Age, corticosteroid treatment and site of mutations affect motor functional changes in young boys with Duchenne Muscular Dystrophy 18
Loss of ambulation in SMA III at the time of disease-modifying treatments: an international study 10
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 7
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 6
Development of the “SMA NNE,” a short neonatal neurological examination for newborns with spinal muscular atrophy 5
The phenotypic spectrum and genetic determinants of severe spinal muscular atrophy in individuals with a single SMN2 copy: an international retrospective observational study 4
Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry 3
Totale 10.165
Salva come PNG Salva come JPEG
Categoria #
all - tutte 39.865
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.865
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 0 1
2021/2022398 13 6 5 72 28 11 9 63 26 19 73 73
2022/20231.150 99 150 66 162 76 144 70 104 164 19 55 41
2023/2024992 34 165 34 88 51 172 152 54 19 49 80 94
2024/20251.684 41 24 108 82 134 92 71 67 249 139 374 303
2025/20265.455 524 135 305 591 872 1.339 724 197 229 267 198 74
Totale 10.165